The intravascular hemolysis of the AHTR produces the classic signs of hemoglobinemia and hemoglobinuria, which are pathognomonic of this condition (they may occur in extravascular HTR if very ...

Omeros Corporation (Nasdaq: OMER) today reported that clinical trial site activation for enrollment is underway for the company’s Phase 3 program evaluating zaltenibart in paroxysmal nocturnal ...

Zaltenibart inhibits the intravascular hemolysis treated by C5 inhibitors as well as the extravascular hemolysis caused by C5 inhibitors in patients suffering from PNH while leaving intact the ...

The disease is currently treated with C5 inhibitors, but these fail to address extravascular hemolysis, a key issue in PNH management. Zaltenibart is an investigational MASP-3 inhibitor ...